Molinos Rio de la Plata SA (MOLI BA) stock market data APIs

ARS2980.9893 -70.7(-2.4%)
as of July 18, 2025
Try our APIs with free plan!

Molinos Rio de la Plata SA Financial Data Overview

Price chart is built with Anychart

Molinos Rio de la Plata S.A. engages in the industrialization and commercialization of food and alcoholic beverages in Argentina and internationally. It operates through Foods and Wineries segments. The company offers edible oils, pasta, dried, frozen, fractionated flour, grass, rice, wines, and sparkling wines. Molinos Rio de la Plata S.A. was incorporated in 1931 and is based in Buenos Aires, Argentina.

Prev. Close 2980.9893
Open 2910.2863
High 3067.8937
Low 2868.3343
52 wk Range 2710-6050
Market Cap 579 843 M
Shares Outstanding 201 M
Revenue 812 368 M
EPS 14.4039
Beta 0.041

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Molinos Rio de la Plata SA data using free add-ons & libraries


Get Molinos Rio de la Plata SA Fundamental Data

Molinos Rio de la Plata SA Fundamental data includes:

  • Net Revenue: 812 368 M
  • EBITDA: -45 343 997 952
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Molinos Rio de la Plata SA Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2023-05-10
  • EPS/Forecast: NaN
GET THE PACKAGE

Get Molinos Rio de la Plata SA End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Molinos Rio de la Plata SA News

Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™ New

Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation f...

Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation f...

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Topline results from Phase 1/2 study on track for March 2021 Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose gro...

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Topline results from Phase 1/2 study on track for March 2021 Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose gro...

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat